Holen Sie sich die Stockscreener-App
11.78
3.60%
-0.44
Schlusskurs vom Vortag:
$12.22
Offen:
$12.34
24-Stunden-Volumen:
2.90M
Relative Volume:
0.77
Marktkapitalisierung:
$1.26B
Einnahmen:
$64.52M
Nettoeinkommen (Verlust:
$-95.55M
KGV:
-11.58
EPS:
-1.0169
Netto-Cashflow:
$-84.65M
1W Leistung:
-23.46%
1M Leistung:
+3.70%
6M Leistung:
+15.83%
1J Leistung:
+75.56%
1-Tages-Spanne:
$11.73
$12.63
1-Wochen-Bereich:
$11.73
$14.75
52-Wochen-Spanne:
$3.84
$16.39
Personalis Inc Stock (PSNL) Company Profile
Firmenname
Personalis Inc
Sektor
Branche
Telefon
650-752-1300
Adresse
6600 DUMBARTON CIRCLE, FREMONT, CA
Compare PSNL vs TMO, DHR, IDXX, A, NTRA
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PSNL
Personalis Inc
|
11.78 | 1.26B | 64.52M | -95.55M | -84.65M | -1.0169 |
TMO
Thermo Fisher Scientific Inc
|
568.26 | 211.18B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
191.50 | 134.62B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
544.32 | 42.94B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
138.57 | 39.14B | 7.23B | 1.41B | 1.09B | 4.979 |
NTRA
Natera Inc
|
261.99 | 37.52B | 2.50B | -226.32M | 71.51M | -1.6412 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2025-05-15 | Eingeleitet | Guggenheim | Buy |
| 2025-03-17 | Eingeleitet | Craig Hallum | Buy |
| 2023-02-06 | Hochstufung | Needham | Hold → Buy |
| 2022-01-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-11-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-03 | Herabstufung | Needham | Buy → Hold |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-09-20 | Bestätigt | Needham | Buy |
| 2021-05-06 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2021-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-11-12 | Bestätigt | Needham | Buy |
| 2020-11-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-10-19 | Eingeleitet | Citigroup | Buy |
| 2020-10-08 | Eingeleitet | BTIG Research | Buy |
| 2020-08-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-08-18 | Eingeleitet | Needham | Buy |
| 2019-09-26 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-07-15 | Eingeleitet | BofA/Merrill | Neutral |
| 2019-07-15 | Eingeleitet | Cowen | Outperform |
| 2019-07-15 | Eingeleitet | Morgan Stanley | Overweight |
| 2019-07-15 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Personalis Inc Aktie (PSNL) Neueste Nachrichten
Tempus to acquire Personalis in $1.5 billion deal to expand MRD capabilities - DOTmed
Personalis Inc (PSNL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Kalpesh Patel: The Fifth MRD Buyout in Less Than a Year - Oncodaily
Why Is PSNL Stock Up 5% After-Hours? - Stocktwits
Why Personalis Stock Is Rising: Medicare Covers Lung Cancer MRD Test - Stocktwits
Tempus makes $1.5B bet to corner cancer-test market - thestreet.com
Tempus AI Makes Billion-Dollar Bet on the Future of Cancer Monitoring - Sahm
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasd - Supply Chain Digital
Tempus AI to Acquire Cancer Diagnostics Firm Personalis for approximately $1.5 Billion, Targeting MRD Market Leadership - finance.biggo.com
Personalis (PSNL) Proxy filing Summary - Quartr
Tempus AI (TEM) On Its Personalis Deal And Whether The Bull Case Is Priced In - Yahoo Finance
Personalis Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Personalis, Inc.PSNL - The AI Journal
Cathie Wood’s Tempus AI Bet Is Bleeding — And the Chart Looks Worse Than Wall Street Thinks - Sahm
Tempus to acquire Personalis, Inc. (PSNL) in cash and stock merger - Stock Titan
BTIG Maintains Personalis(PSNL.US) With Buy Rating, Raises Target Price to $16.25 - Moomoo
Why Is Tempus AI Stock Volatile Tuesday?Personalis (NASDAQ:PSNL), Tempus AI (NASDAQ:TEM) - Benzinga
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Personalis, Inc. (NASDAQ: PSNL) - Morningstar
Tempus AI buys Personalis for $1.5 billion - grafa.com
Personalis: Tempus Bought The Best Part Of The Story (NASDAQ:PSNL) - Seeking Alpha
Tempus AI Buys Personalis for $1.5B to Boost Cancer Monitoring - Medical Device and Diagnostic industry
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Tempus AI to Acquire Personalis for $1.5 Billion to Expand Precision Oncology Platform - HLTH
Tempus AI is acquiring cancer-monitoring firm Personalis in a $1.5 billion stock deal - qz.com
Tempus AI Acquires Personalis: Why Both Stocks Are A Buy Now (NASDAQ:TEM) - Seeking Alpha
Tempus AI acquires cancer-monitoring firm Personalis for $1.5 billion - Yahoo Finance
Tempus to acquire Personalis - Medical Buyer
Tempus AI acquires Personalis in $1.5bn precision oncology-focused deal - Yahoo Finance
Tempus AI snaps up genomics partner Personalis for $1.5 billion - The Pharma Letter
Tempus AI (TEM) to Acquire Personalis in Strategic Move - GuruFocus
Tempus AI (TEM) Is Buying Personalis For $1.5 Billion To Deepen Cancer Monitoring - Yahoo Finance
AI healthcare company acquires US biotech firm for USD 1.7bn - medwatch.com
Personalis (PSNL) Registration Filing Summary - Quartr
TEM, PSNL stocks are falling — why Morgan Stanley still likes Tempus AI’s Personalis deal - MSN
Personalis, Inc. (PSNL) Tempus AI, Inc.M&A CallSlideshow (NASDAQ:PSNL) 2026-07-20 - Seeking Alpha
Daily Brief Health Care: Personalis Inc, ResMed Inc, Ascentage Pharma, Apnimed, UltraGreen.ai, Horizon Quantum Holdings, Scribe Therapeutics and more - Smartkarma
Daily Brief United States: Meta, Gold, Braemar Hotels & Resorts , AIOS, Alarm.Com Holdings, Personalis Inc, Arcbest Corp, New Horizon Aircraft, Jersey Mike's Subs, Crude Oil and more - Smartkarma
Personalis Price Target Announced at $16.25/Share by Lake Street - Moomoo
AI-Driven Tempus Acquires Cancer Diagnostics Firm Personalis for $1.7B in Stock - Briefs Finance
Tempus AI Buys Personalis for $1.5 Billion, and Both Stocks Sink -- Barrons.com - Moomoo
Tempus AI Acquires Personalis For $1.5bn To Expand MRD Cancer Testing - insights.citeline.com
Tempus AI (TEM) plans stock-plus-cash merger with Personalis (PSNL) - Stock Titan
Tempus AI (PSNL partner) to buy Personalis in $1.5B premium stock acquisition - Stock Titan
Tempus to buy cancer test maker Personalis for $1.5 billion - 102.7 WBOW
Tempus AI Announces Merger Agreement to Acquire Personalis - TipRanks
Tempus AI Buys Personalis in $1.7 Billion Precision Oncology Dea - GuruFocus
Expecting Massive Test Growth in Cancer & More, Tempus AI Strikes $1.5B Deal to Buy Personalis - MedCity News
Needham cuts Personalis stock rating on Tempus AI acquisition By Investing.com - Investing.com South Africa
Tempus finds time right for $1.5B Personalis MRD grab - BioWorld News
Tempus AI Buys Personalis in $1.7 Billion Precision Oncology Deal - TradingView
Latham & Watkins Advises Tempus AI on US$1.5 Billion Acquisition of Personalis - Latham & Watkins LLP
Personalis Acquisition Price Warranted by Growth Prospects, Needham Says - Moomoo
Finanzdaten der Personalis Inc-Aktie (PSNL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Personalis Inc-Aktie (PSNL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Chen Richard | President and CMO |
Jul 15 '26 |
Sale |
15.15 |
100,000 |
1,515,000 |
173,880 |
0.02%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):